Make Informed Investment Decisions with Affordable Access to Experts
Dissecting the explosive MGL-3196 36 Week Data in NASH Reported May 31stTicker(s): MDGL, VKTX, NGM Bio, GILD, AGN, PFE
Name: Dr Joel E. Lavine - MD
Institution: Columbia University
- Chief of Gastroenterology, Hepatology and Nutrition at Columbia University Medical Center & the Vice-Chairman for Research in the Department of Pediatrics.
- Currently manages 100 patients with NASH.
- Chair of the Steering Committee of the Nonalcoholic Steatohepatitis Clinical Research Network for the NIDDK for the past 15 years; Led major clinical research trials on treatment of NASH published in the Lancet, Journal of the American Medical Association and the New England Journal of Medicine.
Please describe your background and familiarity with MGL-3196.Added By: joe_mccann
What is your impression of the 36 data?Added By: joe_mccann
When the top-line data is released, we will add additional questions.
- And you can add them as well if you join...
Please give us your updated opinion on the three clinical candidates: MGL-3196, Viking 2809 and the NGM282.
How does the 12 week data for MGL-3196, correspond to 36 week data? Was this a surprise result to you?
What do you think about FGF-19’s mechanism of action, as a potential oncogenic target?
What do you think about the thyroid hormone receptor beta as a target? What percent of the patients with hypothyroidism will have benefit?Added By: joe_mccann
What can biopsies tell you that we can't tell from MRI based methods, ultrasound and other markers like LiverMultiScan?Added By: joe_mccann
Can you make a class comparison of CYMABAY or generally what you thought about their data at EASL and the class of PPAR?Added By: joe_mccann
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.